Lv4
430 积分 2022-11-14 加入
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
24天前
已完结
Dupilumab for COPD with Elevated Eosinophil Counts. Reply
3个月前
已完结
Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature
4个月前
已完结
Inflammatory mechanisms in patients with chronic obstructive pulmonary disease
4个月前
已完结
Type 2 airway inflammation in COPD
4个月前
已完结
Mechanistic links between COPD and lung cancer
4个月前
已完结
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
5个月前
已完结
The Diagnosis and Treatment of Tuberculosis
5个月前
已完结
Brief Report: Emphysema as a Prognostic Factor in Patients With Advanced NSCLC With COPD Receiving Immune Checkpoint Inhibitors
5个月前
已完结
Neoadjuvant immunotherapy in early-stage NSCLC: navigating biomarker dilemmas and special population challenges
5个月前
已完结
皖公网安备34019202002308
